Customized collections enhance safety for individual donors
[by Yu, Suin] GC Biopharma announced on September 24 that its U.S. subsidiary, ABO Plasma (formerly ABO Holdings), has unveiled a new technology designed to improve plasma collection efficiency while simultaneously strengthening donor safety.
This technology builds on the conventional weight-based 바카라 토토 사이트 collection method by incorporating a customized approach that factors in key donor health indicators such as body mass index (BMI) and hematocrit. According to the company, this advancement allows 바카라 토토 사이트 collection tailored to each donor's individual physical condition.
The company highlighted that the new technology reduces the risk of excessive collection while allowing appropriate increases in 바카라 토토 사이트 volume when conditions permit, thereby fostering a more balanced and rational donation environment. In practice, donors with higher hematocrit levels saw their extraction volumes lowered compared to previous years, while others were able to donate increased amounts in line with clinical standards. By ensuring donor safety while improving efficiency, the company reported that the average 바카라 토토 사이트 collection per session has risen by more than 8%.
The system is also expected to support donor health management and accelerate recovery by providing key health indicators such as height, weight, body mass index, and hematocrit. ABO 바카라 토토 사이트 has already rolled out the technology across all of its operating 바카라 토토 사이트 collection centers.
"This technology will not only deliver an improved experience for donors but also enhance the structural efficiency of our 바카라 토토 사이트 business, thereby reinforcing our global competitiveness," Huh Eun-chul, CEO of GC Biopharma.
Conversely, GC Biopharma is currently advancing its post-merger integration (PMI) process following the full acquisition of a 100% stake in ABO 바카라 토토 사이트 in January.